

Supplemental Table 1

Differences between the training cohort and the validation cohort in terms of demographic characteristics and laboratory values

Variable	Validation cohort <i>N</i> =454	Training cohort <i>N</i> =1065	p.overall
Age (years)	76.0 [71.0;82.0]	76.0 [71.0;83.0]	0.736
Male (n%)	261 (57.5%)	615 (57.7%)	0.971
Weight, kg	78.0 [67.8;93.1]	80.0 [67.7;95.1]	0.540
Height, cm	168 [163;175]	168 [160;175]	0.940
Comorbidities, n%			
Hypertension	188 (41.4%)	434 (40.8%)	0.856
Diabetes	178 (39.2%)	447 (42.0%)	0.344
Chronic heart disease	61 (13.4%)	130 (12.2%)	0.564
Cerebrovascular disease	68 (15.0%)	168 (15.8%)	0.753
COPD	29 (6.39%)	100 (9.39%)	0.069
Chronic kidney disease	210 (46.3%)	505 (47.4%)	0.719
Cancer	73 (16.1%)	173 (16.2%)	0.997
Source of infection, n%			
Lung	146 (32.2%)	341 (32.0%)	1.000
Urine	110 (24.2%)	278 (26.1%)	0.482
Blood	190 (41.9%)	427 (40.1%)	0.561
Other(n)	8 (1.76%)	19 (1.78%)	1.000
Vital signs			
Heart rate, bpm	84.5 [74.9;94.7]	82.9 [74.1;94.0]	0.336
Respiratory rate, bpm	19.2 [17.0;22.1]	19.2 [17.1;22.2]	0.979
Temperature, °C	36.8 [36.5;37.1]	36.7 [36.5;37.0]	0.07
Map, mmHg	74.0 [68.0;80.0]	73.2 [68.5;79.8]	0.667

SpO ₂	97.3 [95.6;98.6]	97.3 [95.8;98.6]	0.398
Basal creatinine level, mg/dL	1.35 [0.90;2.40]	1.40 [0.90;2.30]	0.980
Creatinine, mg/dL	1.80 [1.30;3.00]	1.90 [1.30;2.90]	0.829
AKI KIDGO stage			0.766
1	354 (78.0%)	812 (76.2%)	
2	49 (10.8%)	124 (11.6%)	
3	51 (11.2%)	129 (12.1%)	
Creatinine_48 h	2.10 [1.30;3.60]	2.20 [1.50;3.60]	0.383
Laboratory results within 24 h			
Creatinine, mg/dL	2.00 [1.20;3.50]	2.10 [1.30;3.30]	0.480
BUN, mg/dL	29.0 [19.0;49.5]	29.5 [20.0;48.0]	0.621
Lactate, mmol/L	1.90 [1.35;2.90]	1.85 [1.35;2.85]	0.933
PH	7.37 [7.32;7.42]	7.37 [7.32;7.42]	0.700
Hematocrit, g/dL	30.8 [27.4;35.7]	31.1 [27.1;35.5]	0.731
Hemoglobin, g/dL	10.2 [9.00;11.8]	10.2 [8.95;11.8]	0.647
Platelets, ×10 ⁹	172 [124;230]	174 [124;246]	0.580
WBC, ×10 ⁹	12.3 [8.42;16.4]	12.2 [8.75;16.5]	0.872
Albumin, g/dL	3.00 [2.60;3.50]	3.00 [2.60;3.50]	0.595
Sodium, mmol/L	138 [136;141]	138 [135;140]	0.291
Potassium, mmol/L	4.35 [3.95;4.80]	4.30 [3.95;4.75]	0.687
Interventions, n%			
Furosemide use	97 (21.4%)	235 (22.1%)	0.815
Dopamine use	29 (6.39%)	42 (3.94%)	0.053
Norepinephrine use	151 (33.3%)	345 (32.4%)	0.788
Mechvent use (n%)	343 (75.6%)	799 (75.0%)	0.879
CRRT use within 48hours	17 (3.74%)	41 (3.85%)	1.000
Score			

SOFA score	4.00 [2.00;5.00]	4.00 [2.00;5.00]	0.899
GCS score	15.0 [14.0;15.0]	15.0 [14.0;15.0]	0.515
APSIII score	64.0 [48.0;85.0]	65.0 [48.0;86.0]	0.718
Outcomes			
Length of ICU Stay, days	5.38 [3.00;10.3]	5.43 [2.86;10.4]	0.979
Length of Hospital Stay, days	12.8 [8.09;20.2]	13.2 [8.61;21.6]	0.381
ICU mortality (n%)	89 (19.6%)	174 (16.3%)	0.143
Hospital mortality (n%)	115 (25.3%)	268 (25.2%)	0.997

COPD, chronic obstructive pulmonary disease; Map, mean arterial pressure; SpO₂, peripheral oxygen saturation; AKI, acute kidney injury; KIDGO, Kidney Disease Improving Global Outcomes; BUN, Blood Urea Nitrogen; PH, potential of hydrogen; WBC, white blood cell; CRRT, continual renal replacement therapy; SOFA, sequential organ failure assessment; GCS, Glasgow Coma Scale; APSIII, Acute Physiology Score III; ICU, Intensive Care Unit.